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Purpose of the study
This study aims to assess the performance of DRV in
clinical practice, as part of salvage therapy strategies.
Methods
We did retrospective assessment of HIV+ patients who
received DRV at our institution, prescribed as part of a
salvage regimen since 2006. Liver, metabolic and renal
profile were assessed at baseline, after 1 month and
every 3 months. 52 HIV1+ patients have been enrolled;
mean age was 48 (IQR 44-54) years, male 82%, IDUs
29%, MSM 37%, heterosexuals 33%; 15 patients were
HCV or HBV co-infected. All but one were subtype B.
Median CD4 nadir was 82 (IQR 27-234). Thirty-one
patients had AIDS history. Mean time on ARVs was 15
(IQR14-17) years; major mutations were: 8 for NRTI, 2
for NNRTI and 5 for PI.
Results
Median follow-up was 104 weeks (IQR 60—139). Two
patients died: one following a car accident, the other
one due to disseminated Kaposi’s sarcoma. Four patients
stopped DRV: one lost to follow-up, one developed
decompensated diabetes, one rash, one virological fail-
ure. Companion drugs with DRV were NRTI (71%),
etravirine (14%), maraviroc (33%), raltegravir (RAL)
(33%), enfuvirtide (ENF) (33%). Seventeen patients had
changes in therapy during follow up, four patients
stopped NRTIs, among 13 patients who stopped ENF, 5
replaced with RAL. Mean CD4 and HIV-RNA values at
baseline were 251 cells/mm
3 and 4.3 log10 copies/ml,
respectively; CD4 median monthly increase was 9 (IQR
5.1-14.5) cells/mm
3. After 1 month, 49 % had HIV-RNA
< 5 0c o p i e s / m l ;a f t e r1 2 ,2 4a n d3 3m o n t h s9 1 %o f
patients were still undetectable. No statistically signifi-
cant modification were seen in transaminases, creati-
nine, glucose, triglycerides values.
Conclusions
Darunavir was highly effective and well tolerated in
most of patients and showed good metabolic, renal and
liver profile in our cohort where the rate of co-infected
patients was high.
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